Jefferies, a global investment banking firm, updated its outlook on Celcuity Inc (NASDAQ:CELC), raising the price target from $28.00 to $33.00 while keeping a Buy rating on the shares. Currently ...

As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment.

MUSK, a vision-language model, enhances cancer diagnosis by integrating multimodal data, outperforming existing methods in prognosis and treatment predictions.